-
公开(公告)号：US11111290B2
公开(公告)日：2021-09-07
申请号：US16585207
申请日：2019-09-27
Applicant: H. Lundbeck A/S
Inventor： Jan Torleif Pedersen , Kristian Kjaergaard , Lars Østergaard Pedersen , Ayodeji Abdur-Rasheed Asuni , Nina Helen Rosenqvist , Justus Claus Alfred Daechsel , Karsten Juhl , Lena Tagmose , Mauro Marigo , Thomas Jensen , Søren Christensen , Laurent David , Christiane Volbracht , Lone Helboe
IPC: C07K16/18 , A61K39/395 , A61K49/00 , G01N33/68 , A61K39/00
Abstract: The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.
-
公开(公告)号：US10472415B2
公开(公告)日：2019-11-12
申请号：US15645442
申请日：2017-07-10
Applicant: H. Lundbeck A/S
Inventor： Jan Torleif Pedersen , Kristian Kjærgaard , Lars Østergaard Pedersen , Abdur-Rasheed Asuni , Nina Helen Rosenqvist , Justus Claus Alfred Daechsel , Karsten Juhl , Lena Tagmose , Mauro Marigo , Thomas Jensen , Søren Christensen , Laurent David , Christiane Volbracht , Lone Helboe
IPC: C07K16/18 , A61K39/395 , A61K49/00 , A61K39/00 , G01N33/68
Abstract: The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.
-
公开(公告)号：US20190284265A1
公开(公告)日：2019-09-19
申请号：US16371867
申请日：2019-04-01
Applicant: H. Lundbeck A/S
Inventor： Jan Torleif Pedersen , Kristian Kjaergaard , Lars Østergaard Pedersen , Abdur-Rasheed Asuni , Nina Helen Rosenqvist , Justus Claus Daechsel , Karsten Juhl , Lena Tagmose , Mauro Marigo , Thomas Jensen , Søren Christensen , Laurent David , Christiane Volbracht , Lone Helboe
IPC: C07K16/18 , A61K39/395 , A61K49/00 , G01N33/68
Abstract: The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.
-
公开(公告)号：US12129289B2
公开(公告)日：2024-10-29
申请号：US17399205
申请日：2021-08-11
Applicant: H. Lundbeck A/S
Inventor： Jan Torleif Pedersen , Kristian Kjaergaard , Lars Østergaard Pedersen , Ayodeji Abdur-Rasheed Asuni , Nina Helen Rosenqvist , Justus Claus Alfred Daechsel , Karsten Juhl , Lena Tagmose , Mauro Marigo , Thomas Jensen , Søren Christensen , Laurent David , Christiane Volbracht , Lone Helboe
IPC: C07K16/18 , A61K39/395 , A61K49/00 , G01N33/68 , A61K39/00
CPC classification number: C07K16/18 , A61K39/395 , A61K49/00 , G01N33/6896 , A61K2039/505 , C07K2317/24 , C07K2317/30 , C07K2317/33 , C07K2317/34 , C07K2317/51 , C07K2317/515 , C07K2317/565 , C07K2317/75 , C07K2317/76 , C07K2317/92 , C07K2317/94 , G01N2800/2814 , G01N2800/2821
Abstract: The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.
-
公开(公告)号：US11958865B1
公开(公告)日：2024-04-16
申请号：US18467162
申请日：2023-09-14
Applicant: H. Lundbeck A/S
Inventor： Thomas Jensen , Thomas Andersen , Mikkel Jessing , Jacob Nielsen , Henrik Daver , Christopher Richard Jones
IPC: C07D498/22
CPC classification number: C07D498/22 , C07B2200/05 , C07D498/22 , C07B2200/05
Abstract: The present invention is directed to compounds of formula IIa
These compounds are considered useful for the treatment of diseases associated with leucine-rich repeat kinase 2 (LRRK2) such as Parkinson's disease. Furthermore, the invention relates to pharmaceutical compositions comprising said compounds.-
Patent Agency Ranking
公开(公告)号：US10647762B2
公开(公告)日：2020-05-12
申请号：US16371902
申请日：2019-04-01
Applicant: H. Lundbeck A/S
Inventor： Jan Torleif Pedersen , Kristian Kjaergaard , Lars Østergaard Pedersen , Abdur-Rasheed Asuni , Nina Helen Rosenqvist , Justus Claus Daechsel , Karsten Juhl , Lena Tagmose , Mauro Marigo , Thomas Jensen , Søren Christensen , Laurent David , Christiane Volbracht , Lone Helboe
IPC: C07K16/18 , A61K49/00 , A61K39/395 , A61K39/00 , G01N33/68
Abstract: The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.
-
公开(公告)号：US20190284266A1
公开(公告)日：2019-09-19
申请号：US16371902
申请日：2019-04-01
Applicant: H. Lundbeck A/S
Inventor： Jan Torleif Pedersen , Kristian Kjaergaard , Lars Østergaard Pedersen , Abdur-Rasheed Asuni , Nina Helen Rosenqvist , Justus Claus Daechsel , Karsten Juhl , Lena Tagmose , Mauro Marigo , Thomas Jensen , Søren Christensen , Laurent David , Christiane Volbracht , Lone Helboe
IPC: C07K16/18 , A61K39/395 , A61K49/00 , G01N33/68
Abstract: The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.
-
18.发明申请2-Amino-3,5,5-Trifluoro-3,4,5,6-Tetrahydropyridines as BACE1 Inhibitors for Treatment of Alzheimer's Disease 审中-公开2-氨基-3,5,5-三氟-3,4,5,6-四氢吡啶作为治疗阿尔茨海默病的BACE1抑制剂公开(公告)号：US20170066741A1
公开(公告)日：2017-03-09
申请号：US15119639
申请日：2015-02-17
Applicant: H. Lundbeck A/S
Inventor： Karsten Juhl , Mauro Marigo , Lena Tagmose , Thomas Jensen
IPC: C07D401/12 , C07D211/72 , C07D405/12 , C07D413/12 , C07D417/12
CPC classification number: C07D401/12 , C07D211/72 , C07D227/10 , C07D405/12 , C07D413/12 , C07D413/14 , C07D417/12
Abstract: The present invention is directed to novel inhibitors of the BACE1 enzyme. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders for which the reduction of Aβ deposits is beneficial such as Alzheimer's disease.
Abstract translation: 本发明涉及BACE1酶的新型抑制剂。 本发明的单独方面涉及包含所述化合物的药物组合物和该化合物用于治疗Aβ沉积物减少的疾病如阿尔茨海默病的用途。
-
19.发明授权2-amino 3,5,5-trifluoro-3,4,5,6-tetrahydropyridines as BACE1 inhibitors for treatment of Alzheimer's disease 有权2-氨基3,5,5-三氟-3,4,5,6-四氢吡啶作为治疗阿尔茨海默病的BACE1抑制剂公开(公告)号：US09353084B2
公开(公告)日：2016-05-31
申请号：US14625658
申请日：2015-02-19
Applicant: H. Lundbeck A/S
Inventor： Karsten Juhl , Mauro Marigo , Lena Tagmose , Thomas Jensen
IPC: C07D417/12 , C07D211/72 , C07D401/12 , C07D413/12
CPC classification number: C07D401/12 , C07D211/72 , C07D227/10 , C07D405/12 , C07D413/12 , C07D413/14 , C07D417/12
Abstract: The present invention is directed to novel inhibitors of the BACE1 enzyme. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders for which the reduction of Aβ deposits is beneficial such as Alzheimer's disease.
Abstract translation: 本发明涉及BACE1酶的新型抑制剂。 本发明的单独方面涉及包含所述化合物的药物组合物和该化合物用于治疗A和Bgr的减少的病症的用途; 沉积物是有益的，例如阿尔茨海默氏病。
-
20.发明申请2-Amino-3,5,5-trifluoro-3,4,5,6-tetrahydropyridines as BACE1 inhibitors for treatment of Alzheimer's disease 有权2-氨基-3,5,5-三氟-3,4,5,6-四氢吡啶作为治疗阿尔茨海默病的BACE1抑制剂公开(公告)号：US20150232449A1
公开(公告)日：2015-08-20
申请号：US14625658
申请日：2015-02-19
Applicant: H. LUNDBECK A/S
Inventor： Karsten Juhl , Mauro Marigo , Lena Tagmose , Thomas Jensen
IPC: C07D401/12 , C07D417/12 , C07D211/72 , C07D413/12
CPC classification number: C07D401/12 , C07D211/72 , C07D227/10 , C07D405/12 , C07D413/12 , C07D413/14 , C07D417/12
Abstract: The present invention is directed to novel inhibitors of the BACE1 enzyme. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders for which the reduction of Aβ deposits is beneficial such as Alzheimer's disease.
Abstract translation: 本发明涉及BACE1酶的新型抑制剂。 本发明的单独方面涉及包含所述化合物的药物组合物和该化合物用于治疗A和Bgr的减少的病症的用途; 沉积物是有益的，例如阿尔茨海默氏病。
-
-
-
-
-
-
-
-
-
Search Results
20
records
(took 0.032 seconds)
